Racura Oncology Ltd
ASX:RAC
Prices of ASX stocks are not being updated. The latest RAC price on Alpha Spread is from Oct 14, 2026. Financials, forecasts and intrinsic value keep updating.
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Intrinsic Value
The intrinsic value of
Racura Oncology Ltd (RAC) under the Base Case is 2.67 AUD per share.
Compared with the last price of 1.6 AUD on Oct 14, the stock appears
Undervalued by 40% .
The intrinsic value is calculated using valuation multiples.
Do our valuations actually work? See backtest results .
Fundamental Analysis
What Racura Oncology Does
Race Oncology is an Australian biotechnology company that is trying to turn an old cancer drug, bisantrene, into a modern treatment. Its main work is research, lab testing, and clinical development of drug candidates for cancers such as acute myeloid leukemia and other hard-to-treat blood cancers. The company is not a mass-market drug maker; it is a development-stage biotech that is building evidence for its own medicine candidates and related intellectual property.
- Headquarters
- Australia AU
- IPO date
- Jul 13, 2016
Balance Sheet
Continue RAC Research
Decided on Racura Oncology? Get an email when RAC reaches the price you’d buy at. Free with an account.
What is the Intrinsic Value of one RAC stock?
The intrinsic value for
Racura Oncology Ltd (RAC) under the Base Case is 2.67 AUD.
Is RAC stock undervalued or overvalued?
Compared with the last price of 1.6 AUD on Oct 14, the stock appears Undervalued by 40% .